# Shanghai Kechow Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-kechow-pharma

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.kechowpharma.com
- Total disclosed funding: $55M
- Latest round: Series D (Feb 19, 2024)
- Investors on record: 10

## About

Based in Shanghai, China and established in 2014, Shanghai Kechow Pharma, Inc. is a biopharmaceutical company that focuses on researching and developing novel drugs for cancer. Dr. Hongqi Tian, the company's founder, chairman and chief executive officer, has more than 20 years of experience in new drug development. In February 2024, the firm closed a series D+ funding from Wanlian Tianze and Wanlian Securities.

The company’s main business is the research and development of anti-cancer drugs. The company’s self - developed products include the anti-cancer new drug HL085, the targeted anti-cancer new drug Tuolameitini, and the HL-003 chemoradiotherapy protective agent. Its products are used in the field of cancer treatment.

The company generates revenue by providing anti-cancer drugs.

## Funding rounds

- Series D, Feb 19, 2024 — Wanlian Tianze, Wanlian Securities
- Series C, Dec 12, 2019, $45M — Qiming Venture Partners, Decheng Capital, Grains Valley Venture Capital, Sherpa Healthcare Partners
- Series B, Jul 4, 2018 — SDIC Venture Capital
- Series A, Jun 1, 2016, $10M — Grains Valley Venture Capital, YuanBio Venture, China Summit Capital, CCB Private Equity Investment Management

## Investors

- Grains Valley Venture Capital (https://capitalatlas.ai/funds/grains-valley-venture-capital) — Series A, Series C
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- China Summit Capital (https://capitalatlas.ai/funds/china-summit-capital) — Series A
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series C
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series C
- Wanlian Tianze (https://capitalatlas.ai/funds/wanlian-tianze) — Series D
- Wanlian Securities — Series D